About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Stk3tm1Yy
targeted mutation 1, Yingzi Yang
MGI:4422169
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy 		involves: C57BL/6 * CBA MGI:4422182
cn2
 		Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Tg(CAG-cre/Esr1*)5Amc/0 		involves: C57BL/6 * CBA MGI:4422186
cn3
 		Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ 		involves: C57BL/6 * CBA * DBA MGI:4422187
cn4
 		Stk3tm1Yy/Stk3tm1.1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Tg(Prrx1-cre)1Cjt/0 		involves: C57BL/6 * CBA * SJL MGI:4422181
cx5
 		Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy 		involves: C57BL/6 * CBA MGI:4422183


Genotype
MGI:4422182
cn1
Allelic
Composition		 Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Genetic
Background		 involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Stk3tm1.1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk3tm1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk4tm1.1Yy mutation (0 available); any Stk4 mutation (72 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
decreased susceptibility to induced morbidity/mortality ( J:156541 )
• following adenoviral cre injection mice are completely protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced mortality

liver/biliary system
abnormal liver physiology ( J:156541 )
• following adenoviral cre injection mice are completely protected from TNF alpha induced liver damage
decreased hepatocyte apoptosis ( J:156541 )
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis

homeostasis/metabolism
decreased circulating alanine transaminase level ( J:156541 )
• following adenoviral cre injection mice are protected from TNF alpha induced increases in ALT levels
decreased circulating aspartate transaminase level ( J:156541 )
• following adenoviral cre injection mice are protected from TNF alpha induced increases in ALT levels
abnormal response/metabolism to endogenous compounds ( J:156541 )
• following adenoviral cre injection mice are protected from TNF alpha induced liver damage

cellular
decreased hepatocyte apoptosis ( J:156541 )
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis




Genotype
MGI:4422186
cn2
Allelic
Composition		 Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Tg(CAG-cre/Esr1*)5Amc/0
Genetic
Background		 involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Stk3tm1.1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk3tm1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk4tm1.1Yy mutation (0 available); any Stk4 mutation (72 available)
Tg(CAG-cre/Esr1*)5Amc mutation (9 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
liver/biliary system
enlarged liver ( J:156541 )
• at 1 - 7 months after tamoxifen treatment
increased liver tumor incidence ( J:156541 )
• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells
increased hepatocellular carcinoma incidence ( J:156541 )
• all mice treated with tamoxifen at birth develop tumors which display characteristics of hepatocellular carcinoma by 6 months of age

neoplasm
increased liver tumor incidence ( J:156541 )
• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells
increased hepatocellular carcinoma incidence ( J:156541 )
• all mice treated with tamoxifen at birth develop tumors which display characteristics of hepatocellular carcinoma by 6 months of age
increased carcinoma incidence ( J:156541 )
• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells

cardiovascular system
enlarged heart ( J:156541 )
• in some mice at 1 - 7 months after tamoxifen treatment

digestive/alimentary system
enlarged stomach ( J:156541 )
• at 1 - 7 months after tamoxifen treatment

hematopoietic system
enlarged spleen ( J:156541 )
• in some mice at 1 - 7 months after tamoxifen treatment

immune system
enlarged spleen ( J:156541 )
• in some mice at 1 - 7 months after tamoxifen treatment

cellular

growth/size/body
enlarged heart ( J:156541 )
• in some mice at 1 - 7 months after tamoxifen treatment
enlarged liver ( J:156541 )
• at 1 - 7 months after tamoxifen treatment
enlarged spleen ( J:156541 )
• in some mice at 1 - 7 months after tamoxifen treatment




Genotype
MGI:4422187
cn3
Allelic
Composition		 Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Genetic
Background		 involves: C57BL/6 * CBA * DBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Speer6-ps1Tg(Alb-cre)21Mgn mutation (6 available); any Speer6-ps1 mutation (4 available)
Stk3tm1.1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk3tm1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk4tm1.1Yy mutation (0 available); any Stk4 mutation (72 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
liver/biliary system
abnormal liver morphology ( J:156541 )
• dysplasia at 1 month of age
• increase in hepatocyte cell density
enlarged liver ( J:156541 )
• at 1 month of age
abnormal hepatocyte morphology ( J:156541 )
• smaller
• some cells have vacuolated cytoplasm

cellular

growth/size/body
enlarged liver ( J:156541 )
• at 1 month of age




Genotype
MGI:4422181
cn4
Allelic
Composition		 Stk3tm1Yy/Stk3tm1.1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Tg(Prrx1-cre)1Cjt/0
Genetic
Background		 involves: C57BL/6 * CBA * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Stk3tm1.1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk3tm1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk4tm1.1Yy mutation (0 available); any Stk4 mutation (72 available)
Tg(Prrx1-cre)1Cjt mutation (2 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
limbs/digits/tail
abnormal limb bone morphology ( J:156541 )
• shorter skeletal elements in the limbs

skeleton
abnormal limb bone morphology ( J:156541 )
• shorter skeletal elements in the limbs
abnormal cartilage morphology ( J:156541 )
• cell size appears smaller and cell density is increased in the limb cartilage
abnormal long bone hypertrophic chondrocyte zone ( J:156541 )
• proliferating cells are detected in the hypertrophic zone
• apoptosis is decreased compared to controls
• despite the increase in proliferation and decrease in apoptosis cartilage size is not increased
abnormal skeleton physiology ( J:156541 )
• increase in proliferation of cells in the developing limb




Genotype
MGI:4422183
cx5
Allelic
Composition		 Stk3tm1.1Yy/Stk3tm1Yy
Stk4tm1.1Yy/Stk4tm1.1Yy
Genetic
Background		 involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Stk3tm1.1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk3tm1Yy mutation (0 available); any Stk3 mutation (47 available)
Stk4tm1.1Yy mutation (0 available); any Stk4 mutation (72 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased liver tumor incidence ( J:156541 )
• at 12 months of age tumors develop in 2 of 31 mice

homeostasis/metabolism

liver/biliary system
increased liver tumor incidence ( J:156541 )
• at 12 months of age tumors develop in 2 of 31 mice




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/16/2024
MGI 6.23 		The Jackson Laboratory